These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 22013558)

  • 41. Tramiprosate.
    Wright TM
    Drugs Today (Barc); 2006 May; 42(5):291-8. PubMed ID: 16801992
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Positive effects of cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury: an exploratory study.
    Alvarez XA; Sampedro C; Pérez P; Laredo M; Couceiro V; Hernández A; Figueroa J; Varela M; Arias D; Corzo L; Zas R; Lombardi V; Fernández-Novoa L; Pichel V; Cacabelos R; Windisch M; Aleixandre M; Moessler H
    Int Clin Psychopharmacol; 2003 Sep; 18(5):271-8. PubMed ID: 12920387
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of Cerebrolysin on neurogenesis in an APP transgenic model of Alzheimer's disease.
    Rockenstein E; Mante M; Adame A; Crews L; Moessler H; Masliah E
    Acta Neuropathol; 2007 Mar; 113(3):265-75. PubMed ID: 17131129
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Beneficial effect of cerebrolysin on moderate and severe head injury patients: result of a cohort study.
    Wong GK; Zhu XL; Poon WS
    Acta Neurochir Suppl; 2005; 95():59-60. PubMed ID: 16463821
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study.
    Doody RS; Gavrilova SI; Sano M; Thomas RG; Aisen PS; Bachurin SO; Seely L; Hung D;
    Lancet; 2008 Jul; 372(9634):207-15. PubMed ID: 18640457
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Correlations between Alzheimer's Disease Cerebrospinal Fluid Biomarkers and Cerebral Glucose Metabolism after 12 Months of Phenserine Treatment.
    Nordberg A; Kadir A; Andreasen N; Almkvist O; Wall A; Långström B; Zetterberg H
    J Alzheimers Dis; 2015; 47(3):691-704. PubMed ID: 26401704
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dose-dependent effects of Cerebrolysin on EEG and short-term memory of healthy volunteers during control and hyperventilation induced cerebral ischemia.
    Funke M; Fiehler J; Mewes I; Eiselt M; Rother I; Windisch M
    J Neural Transm Suppl; 1998; 53():385-98. PubMed ID: 9700674
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synergistic Increase of Serum BDNF in Alzheimer Patients Treated with Cerebrolysin and Donepezil: Association with Cognitive Improvement in ApoE4 Cases.
    Alvarez XA; Alvarez I; Iglesias O; Crespo I; Figueroa J; Aleixandre M; Linares C; Granizo E; Garcia-Fantini M; Marey J; Masliah E; Winter S; Muresanu D; Moessler H
    Int J Neuropsychopharmacol; 2016 Jun; 19(6):. PubMed ID: 27207906
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The dentate gyrus neurogenesis: a common therapeutic target for Alzheimer disease and senile depression?].
    Tatebayashi Y
    Seishin Shinkeigaku Zasshi; 2003; 105(4):398-404. PubMed ID: 12806901
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combined administration of cerebrolysin and donepezil induces plastic changes in prefrontal cortex in aged mice.
    Alcántara-González F; Mendoza-Perez CR; Zaragoza N; Juarez I; Arroyo-García LE; Gamboa C; De La Cruz F; Zamudio S; Garcia-Dolores F; Flores G
    Synapse; 2012 Nov; 66(11):938-49. PubMed ID: 22826038
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The dentate gyrus neurogenesis: a therapeutic target for Alzheimer's disease.
    Tatebayashi Y; Lee MH; Li L; Iqbal K; Grundke-Iqbal I
    Acta Neuropathol; 2003 Mar; 105(3):225-32. PubMed ID: 12557008
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neuroprotective and consequent neurorehabilitative clinical outcomes, in patients treated with the pleiotropic drug cerebrolysin.
    Onose G; Mureşanu DF; Ciurea AV; Daia Chendreanu C; Mihaescu AS; Mardare DC; Andone I; Spânu A; Popescu C; Dumitrescu A; Popescu M; Grigorean V; Ungur B; Marinescu F; Colibbeanu I; Onose L; Haras M; Sandu A; Spircu T
    J Med Life; 2009; 2(4):350-60. PubMed ID: 20108748
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease.
    Kazim SF; Blanchard J; Dai CL; Tung YC; LaFerla FM; Iqbal IG; Iqbal K
    Neurobiol Dis; 2014 Nov; 71():110-30. PubMed ID: 25046994
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Quality of Life and Utility Measurement in a Large Clinical Trial Sample of Patients with Mild to Moderate Alzheimer's Disease: Determinants and Level of Changes Observed.
    Lacey L; Bobula J; Rüdell K; Alvir J; Leibman C
    Value Health; 2015 Jul; 18(5):638-45. PubMed ID: 26297092
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
    Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial.
    Heiss WD; Brainin M; Bornstein NM; Tuomilehto J; Hong Z;
    Stroke; 2012 Mar; 43(3):630-6. PubMed ID: 22282884
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cerebrolysin: a multi-target drug for recovery after stroke.
    Brainin M
    Expert Rev Neurother; 2018 Aug; 18(8):681-687. PubMed ID: 30004268
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
    Grossberg GT; Edwards KR; Zhao Q
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oral Cerebrolysin enhances brain alpha activity and improves cognitive performance in elderly control subjects.
    Alvarez XA; Lombardi VR; Corzo L; Pérez P; Pichel V; Laredo M; Hernández A; Freixeiro F; Sampedro C; Lorenzo R; Alcaraz M; Windisch M; Cacabelos R
    J Neural Transm Suppl; 2000; 59():315-28. PubMed ID: 10961443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.